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Abstract 
Background 
The South African 2006 Advanced Life Support and Emergency Care Practitioner protocols do not 
currently reflect the latest, best evidence-based practices for emergency care, specifically regarding 
induction agents in head injury patients. Recent evidence has challenged some preconceptions 
regarding the use and safety of Ketamine in head injuries. In response to this, the Health Professions 
Council of South Africa Professional Board for Emergency Care (HPCSA PBEC) has requested a review 
of the emergency care protocols.  
Objectives 
To determine the evidence of effectiveness and safety of intravenous/intraosseous (IV/IO) Ketamine 
as an induction agent for adult patients with traumatic brain injury, the authors aimed to determine 
the all-cause mortality at 30 days, adverse events/effects, morbidity and rate of successful 
intubation associated with ketamine administration, as compared to standard induction agents. 
Research Question 
What is the evidence of effectiveness and safety of IV/IO Ketamine in adult patients with head 
injury, for pre-hospital induction in advanced airway management, compared to standard therapy? 
Methods 
The review followed a tiered approach, where three different tiers of searches were performed for 
articles relevant to the research question. Two authors independently and in induplicate performed 
title, abstract and full-text review for each potentially included article, as well as critical appraisal of 
3 CPGs found in the tier 1 searches. Tier 1 searched for Clinical Practice Guidelines (CPGs), tier 2 for 
Systematic Reviews (SRs) and tier 3 for Randomised Controlled Trials (RCTs) relating to the research 
question. No grey literature searches were performed, but reference lists of included articles were 
searched for relevant articles.  
Main Results 
The authors could not find any studies to include (CPGs, SRs or RCTs) in this review which would 
answer the research question. However, several articles were found which describe ketamine use in 
the Intensive Care Unit (ICU) and surgical patients with regards to intracranial pressure, cerebral 
perfusion pressure and general haemodynamic effects. Another article (RCT) was found which used 
ketamine as an induction agent compared to etomidate to facilitate intubation in critically ill 
patients. These articles provide some helpful insights as to ketamine’s effectiveness and safety for 
induction to facilitate intubation in traumatic brain injury patients in the pre-hospital setting.  
Conclusions 
The authors could not make any recommendations regarding the research question, and the safety 
and effectiveness of ketamine for induction to facilitate intubation in adult traumatic brain injury 
remains unclear. A lack of empirical evidence at RCT level has led to substantial knowledge gaps 
regarding our understanding of Ketamine and its effects in traumatic brain injury patients. 
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Background 
Ketamine, also referred to as Ketalar® or Brevinase®, is a synthetic medication first described in 1962 
by Dr. Calvin Stevens. 1, 1 It is chemically related to phencyclidine (PCP), which it was designed to 
replace due to PCP’s unappealing side-effect profile.2 After being patented in Belgium in 1963, 
ketamine showed much promise as an anaesthetic agent and during 1965, began being used as a 
recreational drug by the public due to its potent hallucinogenic effects. 3 However, clinical data on 
ketamine was still sparse, and in the late 1960’s saw its first real introduction into clinical medicine 
as an anaesthetic agent in the Vietnam War. 2 
Ketamine inhibits the N-Methyl-D-Aspartate (NMDA) receptor, causing a state of dissociative 
anaesthesia, whereby the user has near-complete sensory and motor dissociation from the cerebral 
cortex, without causing complete loss of consciousness. Essentially, a patient cannot perceive the 
world around them, nor is even aware of its existence, and is placed in a dream-like state where the 
brain remains active, but unable to cause any motor stimulation or be innervated by sensory 
stimulation. 4 Some of the beneficial effects of not causing complete loss of consciousness in 
anaesthetised patients are that respiratory function and airway reflexes remain intact at typical 
intravenous injection dosage. 5 
During its use in the Vietnam War, ketamine was regarded as being the “perfect” agent with regards 
to anaesthesia in haemodynamically unstable soldiers as it seemed to not decrease blood pressure 
as significantly, as compared to its benzodiazepine and/or opiate counterparts. 6 However, its side 
effects quickly became apparent as many patients anaesthetised with ketamine had significant 
delirium and “schizophrenia-like symptoms” upon waking. The term “emergence-delirium” was 
coined. 7 This was an expected phenomenon, as ketamine is closely related to PCP which has the 
same emergence effects; these effects are successfully were treated with the concomitant 
administration of a gamma aminobutyric acid (GABA) agonist, such as benzodiazepines. 8 However, 
these effects were not as pronounced as with PCP and ketamine was still considered a viable 
replacement.  
Due to emergence delirium, ketamine made a significant move into veterinary medicine where this 
factor was not considered as unappealing as in human patients. 9 Animal models were used to 
further research the effects, side-effects and toxic-effects of ketamine to better the clinical 
understanding of the medication. 9 During this period, researchers described the secondary 
pharmacological effects of the drug, for which it is so well known today. Apart from the effects on 
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the central nervous system, ketamine has also been known to have significant cardiovascular effects, 
which have been the subject of much debate in recent years 5. It has a directly negative inotropic 
effect, decreasing ventricular contractility, and has little effect on peripheral vascular resistance, 
thereby seemingly reducing systemic blood pressure. 6 However, it has positive chronotropic effects 
and causes positive sympathetic stimulation which leads to catecholamine release and an increase in 
cardiac output and blood pressure. The net result is an increase or maintaining of the systemic blood 
pressure. Thus, in haemodynamically unstable and critically ill patients, ketamine may be more 
beneficial compared to opioids and benzodiazepines, which are known to decrease systemic blood 
pressure when given in doses sufficient to cause anaesthesia. 6 
Ketamine also causes increased cerebral blood flow, which has led to the belief that it has the 
potential to increase intra-cranial pressure (ICP) in patients with traumatic brain injury (TBI). 10–14  As 
a result, it was contra-indicated as an anaesthetic agent for intubation in patients with TBI. There is a 
significant lack of clinical practice guidelines and society statements on the use of Ketamine in TBI. 
However, recent publications have refuted this, 15–20 showing that it increases cerebral blood flow 
and reduces cerebral oxygen demand, 21–24 thereby improving the supply/demand ratio. Secondary 
brain injury due to hypotension and hypoperfusion in TBI has been associated with higher morbidity 
and mortality as compared to the transient increases in cerebral perfusion pressure (CPP) associated 
with ketamine administration. Thus, the haemodynamic stability of ketamine is attractive for 
administration in the critically ill TBI patient; however, the evidence for use in these settings remains 
unclear. 21–24 
Endotracheal intubation is considered the gold standard of securing the airway in severe TBI 
patients. 25 It protects the airway, provides a conduit for ventilation (either manual or mechanical), 
and enables patients to be sedated as a neuroprotective intervention until definitive treatment can 
be provided. 25 However, the ideal induction agent for facilitating intubation in this patient 
population has not been identified. Etomidate and ketamine are popular choices in the South African 
pre-hospital environment, but they both have a significant side-effect profile which makes it difficult 
to establish which is superior.21 South Africa is a low-to-middle income country where accidents and 
injuries form a significant proportion of the country’s burden of disease. 26 Therefore, TBI is a 
common occurrence in most prehospital and emergency centre settings across the country. An 
induction agent which is cheap, readily available and accessible, safe and effective is the ideal agent 
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in a setting such as South Africa due to challenges in resource constraints and access to tertiary care. 
26 
Etomidate has been described as causing relative adrenal insufficiency, which may introduce more 
risk to TBI patients as hypotensive episodes (caused by decreased catecholamine production) may 
lead to hypoperfusion of the injured brain. However, ketamine maintains haemodynamic stability 
which reduces the risk of hypotension and hypoperfusion of the brain and has also been shown to 
have some neuroprotective effects which may protect against hypoxic, ischemic, mechanical and 
chemical neuronal damage.23 These factors may make ketamine the preferred agent for induction of 
TBI patients as it may reduce the mortality and morbidity in the acute emergency TBI patient. 
However, clinicians have been weary of ketamine due to a perceived dogma that ketamine raises the 
ICP, which may be detrimental in severe TBI patient. 21  
The publications warning of ketamine’s use in traumatic brain injury were largely based on 
theoretical arguments in the 1970’s, as few studies which had any clinical arguments were available 
at the time. Most of the publications claiming harm associated with ketamine anaesthesia in TBI 
patients performed their studies on participants with known cerebrospinal fluid abnormalities and 
blockages. 11,12,15 
 Thus, the results have most likely been biased and do not reflect the true potential and safety of 
ketamine.  In the past decade, interest in ketamine had resurfaced in evidence-based medicine and 
publications aimed at disproving ketamine’s harmful effects on ICP have become numerous. 15,17–24 
Thus, a rapid review on the current evidence of ketamine use in adult patients in intubation TBI can 
establish whether ketamine may be useful as an anaesthetic agent in the pre-hospital environment. 
Motivation for Research  
The South African 2006 Advanced Life Support (ALS) and Emergency Care Practitioner (ECP) 
practitioner protocols do not currently reflect the latest, best evidence-based practices for 
emergency care, specifically regarding induction agents in TBI patients. The HPCSA PBEC has recently 
requested a review of the emergency care protocols. Thus, a rapid review will be useful, to 
synthesize the latest evidence in order to update the protocols, inform policy makers, guideline 
developers and guide clinicians 27 regarding the safety and effectiveness of intravenous/intraosseous 
(IV/IO) ketamine for induction in the pre-hospital setting in South Africa. 
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Research Question 
What is the evidence of effectiveness and safety of IV/IO ketamine for pre-hospital induction in 
advanced airway management in adult patients with head injury, with regard to mortality and 
morbidity, compared to standard therapy? 
Objectives 
Primary Objective 
1. To determine the evidence of effectiveness and safety of IV/IO ketamine as an induction 
agent for adult patients with head injury for use by pre-hospital professionals in advanced 
airway management compared to standard therapy in the South African setting.  
Secondary Objectives to Inform the Primary Objective 
1. To determine all-cause mortality of patients with head injuries given ketamine for induction 
at one month (30 days) compared to standard therapy 
2. To determine adverse events/effects associated with the administration of ketamine in 
induction of patients with head injury compared to standard therapy 
3. To determine the morbidity associated with the administration of ketamine for induction of 
patients with head injury compared to standard therapy 
4. To determine the effectiveness of IV/IO ketamine, by measuring the rate of successful 
induction and endotracheal intubation, respectively, of patients with head injury using 
ketamine as induction agent compared to standard therapy for induction.  
 
Methods 
We performed a rapid review of the available literature on ketamine’s effectiveness and safety as an 
induction agent in patients with TBI in the pre-hospital setting, compared to standard therapy. Rapid 
reviews involve the same processes associated with systematic reviews, whereby all available 
evidence is sought regarding a particular topic or research topic. However, rapid reviews streamline 
some of the traditional systematic review methods in order to synthesize evidence in a shorter 
timeframe. 28 
This review has followed a tiered approach, where high-quality Clinical Practice Guidelines (CPGs) 29 
form the first tier of studies which were sought for inclusion, followed by Systematic Reviews (SRs) 
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and finally, Randomised Controlled Trials (RCTs).  If the search strategy could identify a study or 
studies which would answer the research question in a higher tier, the searches would not have 
been continued to the lower tier/s. However, as no studies were found in the first 2 tiers which 
would answer the research question, all 3 tiers of searches were performed.  
 
Criteria for Considering Studies for this Review 
Types of Studies 
First Tier - Clinical Practice Guidelines 
As defined by the Institute of Medicine, clinical guidelines are statements that include 
recommendations intended to optimize patient care that are informed by a systematic review of 
evidence and an assessment of the benefits and harms of alternative care options.30 They are 
traditionally based on one or more high-quality SRs and undergo intensive review, which make them 
such a sought-after source of evidence-based recommendations. CPGs are based on three important 
characteristics: an established evidence base, public and stakeholder consultation and translating 
recommendations into practice.  
High quality CPGs provide an excellent summary of evidence with contextualisation for a specific 
setting. Recommendations/data from high quality CPGs allow us to answer the research question 
rapidly as they should include evidence from SRs and RCTs for an intervention question.  
Second Tier - Systematic Reviews 
SRs follow rigorous methods to systematically search for, appraise and synthesise research evidence 
for a particular research question. 31 It is the explicit and systematic approach that distinguishes 
systematic reviews from traditional reviews and commentaries.32 A systematic review often 
identifies several studies addressing the same question. Thus, if the studies’ methodologies and 
sample populations are comparable, it would be reasonable to pool the findings in a quantitative 
(e.g. meta-analyses) or qualitative (e.g. narrative review) synthesis. The synthesised results can then 
be used by policy makers and guideline developers to influence decision-making by clinicians. 33 Due 
to their explicit and rigorous methods to produce synthesised evidence regarding the effectiveness 
of an intervention, systematic reviews formed the second tier of studies sought for inclusion.  
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Third Tier - Randomised Controlled Trials 
RCTs are considered the gold standard of evaluating the effectiveness of interventions in primary 
research. No other research methodology provides the same level of reliable evidence on the 
effectiveness of an intervention, as the processes used during the conduct of an RCT minimise 
selection bias and confounding factors which may influence the results. RCTs were the third tier of 
studies sought for inclusion in this review.  
Types of Participants 
Adults with TBI who require induction and intubation in either the pre-hospital or emergency 
department settings. TBI was defined as per the included studies’ criteria for TBI, but should have 
contained the following common indicators: The patient’s history/mechanism of injury or symptoms 
suggesting head injury, 34 or a Glasgow Coma Scale (GCS) ≤13/15.35 
In this review the authors included both the prehospital and emergency centre as primary 
population groups in the searches, as the key demographic of interest was TBI in the acute 
emergency setting. Although the data may not vary much between these two groups in the key 
aspects, a distinction is made between them, and patients who have been admitted to wards 
(surgical or recovery) and the ICU, as the clinical setting in these environments are fundamentally 
different from the emergency centre and prehospital environment.  
 
Types of Interventions 
Ketamine administration as an anaesthetic agent to facilitate endotracheal intubation in the pre-
hospital setting. Proprietary names of Ketamine which were specified for inclusion include Ketamine, 
Ketalar™ and Brevinase™. Other proprietary names have not been included in the search strategy.  
Types of Comparators 
In this review, Ketamine as an anaesthetic agent to facilitate endotracheal intubation in patients 
with TBI was compared to “standard therapy”, where standard therapy refers to the commonly used 
induction modalities and medications currently available in the South African Pre-hospital 
environment. This includes etomidate, midazolam and the midazolam/morphine cocktail. In the 
searches performed for this review, it was accepted that doses among these various medications 
may not be uniform, or similar to what is prescribed in the South African protocols. As an example, 
below is an outline of standardised dose ranges for the anaesthetic agents commonly used in the 
South African Pre-hospital environment. 
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●        Etomidate: 0.2 - 0.3 mg/kg                                        (actual body weight) 36–39 
●        Ketamine: 1 - 3 mg/kg                                                 (ideal body weight) 36,39,40 
●        Midazolam: 0.1 - 0.3 mg/kg                                       (actual body weight) 36,39,40 
●        Morphine and Midazolam (any dose)                   (actual body weight) 
For the purposes of this review, the search was not limited to studies which only compare Ketamine 
to the above medications, but has included studies that use other medications to induce patients for 
intubation in the pre-hospital environment as well. 
Types of Outcome Measures 
For each tier of studies for inclusion (CPGs, SRs and RCTs) the outcomes, as defined below, would 
have been extracted:  
● For CPGs, recommendations and evidence matrices that answer the research question 
would have been extracted and, if reported, the pooled data (meta-analysis or network 
meta-analysis) or individual effects (e.g. for a single RCT) would also have been extracted. If 
reported, summary of findings (SoF) tables and evidence quality grading matrices would also 
have been sought and extracted. 
● For SRs, the pooled data (meta-analysis or network meta-analysis) per outcome or individual 
effects (e.g. for a single RCT) will be extracted if reported. If reported, SoF tables and 
evidence quality grading matrices would also have been extracted.  
● For RCTs, the below outcomes were searched for directly. 
Primary Outcomes 
All-cause mortality at one month                 
Secondary Outcomes 
1. Adverse effects. An adverse event was defined as an event for which a causal relationship 
between the intervention and the event was a reasonable possibility (e.g. convulsions, 
unexplained delirium and emergence delirium) 
2. Morbidity associated with the administration of Ketamine for induction of patients with 
head injury compared to standard therapy 
3. Rate of successful endotracheal intubation of patients with TBI using Ketamine as induction 
agent compared to standard therapy for induction  
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Search Methods 
Electronic Searches 
The electronic searches were performed in the databases mentioned below for each respective tier 
of inclusion, i.e. CPGs, SRs and RCTs. The relevant search strategies are outlined in Appendix 1. For 
each tier of inclusion, a separate search strategy was developed as the databases for RCTs, CPGs and 
SRs all have different search keywords, characteristics and MeSH (Medical Subject Headings) terms. 
For example, PubMed uses MeSH terms, whereas Scopus does not. The “English” language filter was 
applied to all electronic searches once the search strategy has been entered into the appropriate 
database, but no publication date filters were added. The search strategies used in this review were 
developed and validated in conjunction with an information and searching specialist at University of 
Cape Town health sciences library. 
Clinical Practice Guidelines 
Clinical Practice Guidelines (CPGs) pertaining to the research question were searched for on the 22nd 
September 2015 using the search terms: “Ketamine OR Ketalar OR Brevinase AND Head Injur* OR 
Brain Injur* OR traumatic brain injur* OR Head trauma”, or a variation thereof in databases which 
did not recognize the asterisk function in searches, in the following databases:  
● Scottish Intercollegiate Guidelines Network (SIGN) 
● National Institute for Healthcare Excellence (NICE)  
● New Zealand Guidance Group (NZGG)  
● National Health and Medical Research Council (NHMRC)  
● Trip  
● Scopus  
● Ebscohost  
● Pubmed  
See: appendix 1.1 for specific CPG search strategies 
Systematic Reviews 
Systematic reviews were searched for on the 1st October 2015 using the search term “Ketamine AND 
(Head Injur* OR Brain injur*)” or an appropriate adaptation in databases which do not recognize the 
asterisk function in search terms, in the following databases:  
● Cochrane Central Register of Controlled Trials (CENTRAL) 
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● Scopus  
● PubMed  
See: appendix 1.2 for specific SR search strategies 
Randomised Controlled Trials 
RCTs were searched for on the 20th of January 2016 using the search terms as defined in appendix 
1.3, in the following databases: 
● Pubmed 
● Medline 
● Scopus 
● Cochrane CENTRAL Library 
See: appendix 1.3 for specific RCT search strategies 
Searching Other Sources 
Reference lists of included studies (CPGs, SRs, and RCTs) were searched for identifying other 
potential studies for inclusion. The authors have not searched for ‘grey literature’ and/or 
unpublished works, due to operational time constraints. One study author, Brian Driver 41, was 
contacted to obtain a full-text article, but the study had not yet been completed by the time as this 
review was completed. This study and its potential future implications for this review are discussed 
further below. Trial registries have not been searched 
Data Collection and Management 
Selection of Studies 
After the search results were produced, EndNote reference management software was used to 
remove any duplicate records. Two review authors (PS and MM) independently and in duplicate 
screened titles and abstracts to remove obviously irrelevant reports and retrieve the full-text of 
potentially relevant reports. PS and MM resolved any disagreements regarding inclusion or exclusion 
of a study by discussion, and if resolution was not obtained, consultation with an independent third 
party (AL) was the planned solution. However, consultation with an independent third party was 
never required as all disagreements were resolved with discussion. Neither author was blinded to 
the names of the study authors, institutions, journal of publication nor results, as this practice had 
uncertain benefit in protecting against bias. 42 Three flow diagrams were created to report the 
process of inclusion and exclusion of studies, and delineate the numbers of studies excluded during 
the process. These can be found in-text under the ‘Results’ section.  A table of excluded studies was 
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created from the full-text articles deemed not for inclusion by the review authors (PS & MM), and 
included a brief explanation as to the reason for exclusion. We reported any included studies in the 
included studies table and excluded studies in excluded studies table. 
Data Extraction and Management 
The two reviewers planned to independently and in duplicate extract data from included studies 
using a pre-specified data extraction form for CPGs, SRs or RCTs respectively. The data extracted 
would have relied on pre-specified outcomes which pertain to the research question and the 
relevant objectives.  
The following information would have been collected from an included study:  
● Study Particulars (Review author contact details, study or report registration ID, citation and 
name/s of person extracting data) 
● Eligibility of Inclusion (Confirmation that study is eligible for inclusion as per protocol and 
does not meet criteria for exclusion) 
● Methods (study aim/s, design, duration) 
● Participants and Setting (study population and location, recruitment method, inclusion and 
exclusion criteria, informed consent obtained where applicable, number of participants in 
each arm (if RCT) or number of included participants in pooled analysis (if SRs or CPG), rural 
or urban setting, developing or developed country, subgroups measured, subgroups 
reported) 
● Interventions and comparators (Ketamine hydrochloride or other preparation, dosage, route 
of administration, time of medication administration, place of administration) 
● Outcome measures coupled with results (outcome definition/name, person measuring or 
reporting, all-cause mortality at 30 days or longer where available, adverse effects, 
morbidity, comorbidities, success rates of intubation) 
● Results (continuous variables (mean or mean difference) of outcome data with measures of 
variability (standard deviation), dichotomous data such as total number of events in each 
arm and numbers of participants (if RCT), meta-analysis results or network meta-analysis 
results (SRs), clinical practice recommendations from CPGs with summary of findings tables 
or equivalent measures of effect measure quality) 
● Applicability (populations included and excluded, disadvantaged groups, applicability to 
developing countries) 
15 
 
 
Critical Appraisal 
Clinical Practice Guidelines 
To appraise CPGs the Appraisal of Guidelines for Research and Evaluation II (AGREE II) appraisal tool 
was used. 43 The purpose of AGREE II is to provide a framework to assess the quality of guidelines, 
provide a methodological strategy for the development of guidelines; and inform what information 
and how information ought to be reported in guidelines. The AGREE collaboration has defined the 
quality of guidelines as “the confidence that the potential biases of guideline development have 
been addressed adequately and that the recommendations are both internally and externally valid, 
and are feasible for practice”. 43 
The AGREE II tool has six domains which all appraise difference facets of the guideline document. 
These six domains are split (not uniformly) into 23 items which require appraisal by the appraiser/s. 
Upon completion of the 23 items (and resultantly, the 6 domains) and overall assessment of the 
guideline will be made by all appraisers, and a final score assigned to the guideline document. The 
final score will determine the guideline's overall quality, based on the score itself and the subjective 
judgements of the appraiser/s. The score provides a subjective estimate of the guideline quality, as 
no minimum acceptable score or acceptable score range has been defined by the AGREE II authors 
to date.  
A guideline would have been considered high-quality if the AGREE II score is considered acceptably 
high by the appraisers in this review (PS & MM), when appraised independently and in duplicate . If 
there was a disagreement between the two review authors (PS & MM) which could not be resolved 
through discussion, then the independent third party (AL) would have been consulted for resolution. 
A guideline which did not meet the desired requirements to be considered high-quality (above 60% 
adherence to AGREE II items) was assigned a low quality rating and excluded from the study.  
Systematic Reviews 
To appraise systematic reviews, the Assessment of Multiple Systematic Reviews (AMSTAR) appraisal 
tool would have been used. AMSTAR is a tool specifically designed to appraise systematic reviews of 
interventions and is an 11-item questionnaire that is used to assess their methodological quality.44 It 
provides a framework for the appraisal of a systematic review’s methodological quality, validity 
(both internal and external) and risk of bias.  
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To apply AMSTAR, each systematic review was to be appraised by two reviewers (PS and MM) and 
judged against the criteria set out in the appraisal tool. AMSTAR determines the methodological 
quality of a systematic review by assessing the presence of: 
● an a priori design; 
● duplicate study selection and data extraction; 
● a comprehensive literature search; 
● the use of status of publication as an inclusion criterion; 
● a list of included/excluded studies; 
● characteristics of included studies; 
● documented assessment of the scientific quality of included studies; 
● appropriate use of the scientific quality in forming conclusions; 
● the appropriate use of methods to combine findings of studies; 
● assessment of the likelihood of publication bias; and 
● documentation of conflict of interest  
Upon completion of the appraisal questionnaire, a point is awarded for each of the 11 items which 
have been satisfactorily addressed in the review being appraised. A point of 0 is assigned to items 
which are not met, unclear or not applicable. Thus, a maximum score of 11 out of 11 is a systematic 
review which likely has minimal risk of bias, and a minimum score of 1 out 11 is a systematic review 
which almost certainly has one or several sources of bias. 44 
An overall score relating to review quality is then calculated (the sum of the individual item scores). 
AMSTAR characterises quality at three distinct levels: 8 to 11 is high quality, 4 to 7 is medium quality, 
and 0 to 3 is low quality. The principals of the AMSTAR tool can be used to demonstrate aspects of 
systematic review methodology that influence the overall quality of a review. 45 Ideally, this review 
aims to only include studies which fall within the high quality category. However, in some cases, if 
better quality studies could not be found for inclusion, studies with medium quality would have 
been included. 
Randomised Controlled Trials 
The Physiotherapy Evidence Database Scale (PEDro) 46 is a tool to appraise the quality of an RCT. It 
consists of 11 items that are designed to test the external and internal validity, as well as the 
statistical interpretability of an RCT. The first item decides its external validity, and the other 10 
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items are summed to give a score out of 10 for the particular RCT. For this review, a PEDro score of 
more than 5 out of 10 would have been the benchmark for inclusion.  
The Cochrane Collaboration’s ‘Risk of Bias’ appraisal tool would also have been used to appraise 
RCTs in terms of their stated or perceived risk of bias. The Risk of Bias tool has six domains, which 
assess the factors identified as being likely indicators of bias in RCTs. RCTs will be appraised 
independently and in duplicate by both review authors (PS and MM) and the following domains 
addressed: Sequence Generation, Allocation Concealment, Blinding (blinding of participant and 
personnel, blinding of outcome assessors), incomplete outcome data, selective outcome reporting 
and other risks of bias.42 
Data Synthesis and Evidence Synthesis 
Clinical Practice Guidelines 
CPGs which have gone through full-text review and have been included would undergo critical 
appraisal by using AGREE II. Outcomes which met the requirements of this review would have been 
adapted, adopted or contextualised to the outcomes as specified in this review. The data would then 
have been synthesised narratively to answer the research question and provide recommendations 
for the effectiveness and safety of Ketamine as an anaesthetic agent in patients who require 
intubation in the prehospital setting. Decisions to adopt, adapt or contextualise 47 guidelines 
recommendations would have been made in conjunction with MM and AL.  
Systematic Reviews 
If systematic reviews were found which answer the research question and have been appraised to 
be of sufficient quality to be included in the review, their results and recommendations would have 
been synthesised based on the type of data and outcomes found. The results from SRs and RCTs 
would have been graded according to the National Health and Medical Research Council (NHMRC) 
Body of Evidence Matrix (BEM) for rapid reviews.48 
Randomised Controlled Trials 
The data obtained from RCTs would have been analysed in one of two ways, either through narrative 
review, or if possible, meta-analysis.  Narrative synthesis would attempt to rank interventions based 
on study reported effect measures and risk of bias assessments and would describe study 
characteristics as it would have been seen in the table of included studies. Meta-analysis would have 
been performed if multiple RCTs were found which are methodologically and clinically similar, with a 
chi2 or I2 statistic which was not indicative of significant heterogeneity. We would have used a fixed-
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effect meta-analysis if studies were estimating the same treatment effect (no statistical 
heterogeneity) and a random-effects meta-analysis if studies showed substantial heterogeneity (I2 
>80%). Subgroup analysis would have been performed if appropriate (defined in the subgroup 
analysis section). Since it is possible that RCTs comparing multiple combinations of treatment 
interventions (e.g. ketamine vs morphine vs etomidate, etc.) may have been found, a network meta-
analysis (NMA) could have been performed. As network meta-analysis is an advanced form of 
evidence synthesis this statistical aggregation might have been outside of the scope of this 
dissertation and would only have been performed if time and resources considerations could be 
met. If NMA was warranted but not performed, this would then have been explicitly stated in the 
results section. If NMA was performed, standard NMA methods would have been used as defined by 
the Cochrane Multiple Interventions Methods Group (http://cmimg.cochrane.org/).  
Evidence generated from synthesised RCTs would have been graded according to the National 
Health and Medical Research Council (NHMRC) Body of Evidence Matrix (BEM) for rapid reviews as 
mentioned previously. If data from both SRs and RCTs were available then both would have been 
used in the NHMRC BEM.   
Sub-group Analysis 
We planned to conduct sub-group analysis as recommended by Deeks 200149 to investigate 
differences between two or more subgroups. Subgroup analysis would have been performed if there 
were adequate studies to justify such analysis. 
Pre-defined sub-group characteristics included: 
● Medical Practitioner compared to paramedic  
● Rapid Sequence Intubation (RSI) versus non-RSI (paralytic administered vs. no paralytic 
administered) 
● Low-to-middle income countries (LMIC) and High-income countries (HIC) 
Results 
Results of the Searches 
Clinical Practice Guidelines - Study Flow Diagram 
Figure 1 details the process followed for the CPG searches, full-text review and AGREE II appraisals. 
86 records were found (85 records identified through database searches and 1 record identified 
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through other sources). Of those, 69 records were excluded in the title/abstract screening. The 
remaining 17 potential included articles then underwent full-text review and all 17 records were 
excluded, with reasons for the exclusion provided in Table 1.1: Tier 1 table of excluded studies.  
Three of the CPGs, (Green, et al. 50, Mayglothling, et al. 51 and Jensen, et al. 52) were appreciably close 
to the research question, and although were excluded from the review, the authors performed 
critical appraisal of them using AGREE II as an indication of the quality of guidance currently 
available for healthcare providers regarding the research question. All three CPGs scored low on the 
AGREE II assessment, and were determined to be of a low quality. This indicates that the guidance 
currently available to healthcare providers regarding this topic is very poor. The AGREE II scores 
obtained by the 3 CPGs can be found in Appendix 2. 
 
   Figure 1: Clinical Practice Guidelines Flow Diagram (Tier 1) 
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Systematic Reviews - Study Flow diagram 
Figure 2 details the process followed for the SR searches and full-text review. 80 records were found 
(82 records identified through database searches and 3 records identified through other sources, 
with five records which were duplicates removed). Of those, 59 records were excluded in the 
title/abstract screening. The remaining 21 potential included articles then underwent full-text review 
and all were excluded, with reasons for the exclusion provided in Table 1.2: Tier 2 table of excluded 
studies. 
 
   Figure 2: Systematic Review Flow Diagram 
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Randomised Controlled Trials - Study Flow Diagram 
Figure 3 details the process followed for the RCT searches and full-text review. 385 records were 
found (403 records identified through database searches, but 18 records were duplicates and 
removed). Of those, 376 records were excluded in the title/abstract screening. The remaining nine 
potential included articles then underwent full-text review and all were excluded, with reasons for 
the exclusion provided in Table 1.3: Tier 3 table of excluded studies. 
 
   Figure 3: Randomised Controlled Trial Flow Diagram 
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Description of Included Studies 
The authors could not find any studies to include (CPGs, SRs or RCTs) in this review which would 
answer the research question.  
Description of excluded studies 
References to the excluded studies (CPGs, SRs and RCTs) can be found below, under the heading 
‘References to Excluded Studies’. The excluded studies with their respective reasons for exclusion 
are described in Tables 1.1, 1.2 and 1.3, whereas Tables 2.1, 2.2 and 2.3 contain summaries of the 
excluded studies which were most relevant to the review’s research question. It includes comments 
by the author describing its relevance to the research question, as well as to healthcare providers in 
the South African pre-hospital or emergency department settings.  
Description of Quality of Reporting 
AGREE II 
The AGREE II assessment was performed as per the guidelines set out in the AGREE II appraisal tool 
manual.  43 Appendix 2 reflects the aggregate scores (MM and PC) obtained by each CPG, for each 
respective domain, as well as a graphical representation of the aggregate scores obtained by each of 
the 3 CPGs on which AGREE II was performed. AGREE II was used as a guide to determine which 
guidance documents were ‘true’ CPGs, as many articles which are published as CPGs tend not to be 
true CPGs. E.g. an end-user document for guidelines on seizure management, but which has not 
been performed using the methods and rigour required with a true CPG.  
AMSTAR 
As all systematic reviews found in the searches were excluded at full-text review, no systematic 
reviews were appraised using AMSTAR.  
PEDRO and Cochrane Risk of Bias (ROB) 
As all randomised controlled trials found in the searches were excluded at full-text review, no 
randomised controlled trials were appraised using PEDRO and Cochrane Risk of Bias (ROB) tool.  
Ongoing trials/studies 
An RCT of great interest to the authors is currently underway by Driver, et al.1 They are comparing 
ketamine to etomidate for rapid sequence intubation in the emergency centre on all adult, non-
prisoner patients who present to an urban level 1 trauma centre. Their research outcomes match 
our review’s very closely, as they are comparing mortality, intubation success, intubation 
complications and short-term safety outcomes between ketamine and etomidate in these patients. 
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They presented their preliminary findings at a conference and found no difference in any of the 
study outcomes between the two groups. This trial is registered at clinicaltrials.gov: NCT01823328. 
The study authors were contacted to obtain a full-text, if it were available. But, as the study has not 
been completed by the time of submission of this review, it could not be included. The principal 
investigator of the RCT has informed the authors that they plan to do a sub-group analysis of TBI 
patients in their study, which would be of great value to our review. 
Effects of the Intervention 
As no studies were included in this review, the authors are uncertain regarding the effectiveness and 
safety of Ketamine for induction to facilitate intubation in adult TBI patients and are thus unable to 
make recommendations due to a lack of empirical evidence or guidance for the pre-hospital setting.  
Discussion 
We did not find any CPGs, SRs or RCTs which answer the research question regarding the safety and 
effectiveness of IV/IO ketamine for induction to facilitate intubation in adult TBI patients in the pre-
hospital setting. The effect of ketamine on mortality, morbidity, adverse effects and intubation 
success rates in this patient population is not yet clear. However, several articles were found which 
describe ketamine use in Intensive Care Unit (ICU) and surgical patients with regards to intracranial 
pressure, cerebral perfusion pressure and general haemodynamic effects. 49-54 Another article (RCT) 
used ketamine as an induction agent compared to etomidate to facilitate intubation in critically ill 
patients. 49 Although these articles would be excluded as they do not match our population of 
interest (TBI), intervention, comparator and/or outcome, they may provide some helpful insights as 
to ketamine’s effectiveness and safety for induction to facilitate intubation in TBI patients in the pre-
hospital setting. These articles are discussed below. The most relevant articles regarding the 
research question which were found in the tier 1, tier 2 and tier 3 searches, are narratively 
summarised in Tables 2.1, 2.2 and 2.3, respectively. 
In total, the authors screened 551 potentially relevant papers (86 under tier 1, 80 under tier 2 and 
385 under tier 3), screened their reference lists and contacted an author of an RCT 41 to obtain the 
full-text. It is possible that the authors may have missed a potentially relevant article due to some 
limitations of the study design, such as the exclusion of grey literature, articles published in 
languages other than English and the exclusion of studies which did not have the desired 
type/methodology, such as cohort, literature review, case/control and case series studies. However, 
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due to the thorough search strategies and the use of a tiered approach it is highly unlikely that a 
relevant article published in English was missed.  
Table 2.1 provides a summary of CPGs on ketamine which may provide some insights into the 
intervention effect. Green, et al.50 provided an argument for ketamine use in TBI patients, and have 
subsequently removed TBI as a relative contraindication for ketamine administration from their 
2011 update of the original guideline published in 2004. They stated that newer evidence suggests 
that ketamine does not seem to cause clinically significant increases in intracranial pressure, and 
that increases are likely to be minimal and not sustained if they do occur in patients with normal 
ventilation. The resulting cerebral vasodilation caused by ketamine may in fact improve cerebral 
perfusion, and thereby improve outcomes of TBI patients. Also, given the lack of any supportive 
evidence that ketamine may cause harm to the acutely traumatised brain, the historical 
contraindication to its use seems unsupported.  
This thought is shared by the authors of this review, as the clinical evidence available does not seem 
to substantiate that ketamine causes harm to the acutely injured brain. The historical publications 10–
14,16 which led to the contraindication of ketamine for TBI patients, based their studies on patient 
populations which had their cerebrospinal fluid (CSF) flow naturally or artificially blocked. As 
ketamine causes cerebral vasodilation, the brain would not be able to compensate for the resulting 
rise in intracranial pressure by shunting CSF away from the brain, causing an increase in intracranial 
pressure. Thus, these studies were inherently flawed, as they proved that ketamine could cause a 
rise in intracranial pressure, but only if the patient’s CSF flow is disrupted. Thus, in a normal patient 
population where CSF flow is, or is assumed to be, normal, these effects would likely not occur, as is 
shown by recent publications on ketamine where no, or minimal intracranial pressure increases (and 
in some cases, decreases) have been found. 16, 18-24 
Mayglothling et al.51 stated that “there are no convincing studies evaluating the effects of ketamine 
on ICP when used as an induction agent.” Although the authors stated that etomidate is currently 
the preferred induction agent for rapid sequence intubation in many centres (due to its 
haemodynamic stability, rapid onset and familiarity with its use), they emphasised that it is not 
without side-effects. However, care should be taken in using etomidate for induction of trauma 
patients, as the adrenal insufficiency sometimes caused by etomidate may lead to worse patient 
outcomes. Jensen et al 50 recommend that ketamine be considered for induction for RSI in 
haemodynamically unstable patients, and be avoided (or used with extreme care) in patients with 
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ischemic heart disease. However, the authors were silent regarding ketamine use in patients with 
TBI.  
The overall reporting quality of CPGs was relatively poor, considering that for an article to be 
considered a true CPG, reporting quality should be exemplary and supplemented by a systematic 
review of the literature. The AGREE II Collaboration 43 has outlined several reporting quality 
indicators which should be met for a CPG to be considered of a high quality. However, the CPGs 
found in the tier 1 search were considered low quality according to the AGREE II tool. This, in 
addition to the author's assessment of the CPGs found, have led to their overall exclusion from the 
review. Other than Green et al., no other CPG found made recommendations on the use of ketamine 
as an induction agent to facilitate intubation in TBI patients. This is likely as a result of the paucity of 
evidence and/or significant controversies regarding the topic. 
Table 2.2 provides a summary of SRs on ketamine which may provide some insights into the 
effectiveness and safety of ketamine for induction of TBI patients. Cohen et al.51 was a systematic 
review published in 2015 where the authors wanted to establish whether ketamine raises 
intracranial pressure or worsens neurological outcomes. Their review included studies which 
reported human data on the effect of intravenous ketamine used as an infusion or bolus dose in 
patients who had previously been intubated or who were being intubated at data collection. The 
majority of the articles they included in their review were of TBI patients in the intensive care unit.  
They found conflicting results amongst the included studies, with some reporting increases in 
intracranial pressure and others a decrease in intracranial pressure post-administration. However, 
neither was sustained long enough to be considered clinically significant. The authors stated that the 
available data suggests that ketamine, compared to other induction agents commonly used to 
intubate adult patients in the emergency department, does not have an adverse effect on 
intracranial or cerebral perfusion pressures, neurologic outcomes or mortality. However, their 
review was limited by a lack of large, well-designed and -conducted randomised controlled 
addressing the topic, and they based their results on patients not commonly found in the emergency 
department (i.e. intensive care or surgical patients).  
There is a lack of large, pragmatic, well-conducted randomised controlled trials to provide an 
evidence base for the use of ketamine in TBI patients. Both CPGs and SRs are inherently reliant on 
scientifically robust study designs (such as RCTs) to strengthen their evidence base and 
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recommendations for an intervention. When one considers the grading of evidence using the 
National Health and Medical Research Council Evidence Grading Matrix 48, a high quality RCT with 
low risk of bias can produce a level 1 evidence base for a particular recommendation, which is the 
highest level. This emphasises the need for high quality RCTs with low risk of bias regarding this 
topic, as systematic reviews and clinical practice guidelines based on poor quality evidence, will yield 
poor quality recommendations to inform practice. 
Wang et al.54 was a systematic review published in 2014 where the authors wanted to establish 
whether ketamine had an effect on intracranial pressure (ICP) and other cerebral hemodynamics, to 
determine whether ketamine was safe for patients with hemodynamic instability and TBI. They 
performed meta-analyses for intracranial pressure, mean arterial pressure and cerebral perfusion 
pressure, respectively. The first meta-analysis showed that ketamine led to no difference in ICP as 
compared to opioids (mainly sufentanil and fentanyl) [MD=1.94; 95% CI, -2.35, 6.23. I2 = 85%; P = 
0.38] and followed a random-effects model. The second meta-analysis for mean arterial pressure 
followed a fixed effects model, and data were derived from 3 articles. No statistical difference was 
found in mean arterial pressure values between the groups [MD = 0.99; 95% CI, -2.24, 4.22; I2 = 0%; 
P = 0.55]. Data from 4 articles (all RCTs) were used for the analysis of cerebral perfusion pressure 
and followed a random effects model. Ketamine administration was comparable with opioids in the 
maintenance of cerebral perfusion pressure. [MD = -1.07; 95% CI, -7.95, 5.8; I2 = 83%; P = 0.76]. 
Thus, in none of the analyses performed by the authors was a significant difference in outcome 
detected.  
To the author's knowledge, Wang et al. was the first study to perform meta-analyses on the topic. 
However, the two meta-analyses presented in their systematic review regarding intracranial 
pressure and cerebral perfusion pressure, had high heterogeneity at I = 85% and I = 83%, 
respectively. Although this may still yield useful results, it reflects a similar level of uncertainty and 
heterogeneity in the evidence. Until large, high-quality, pragmatic randomised controlled trials are 
performed to strengthen the evidence base and reduce the conflicting study results emanating from 
smaller, lower-quality studies, these meta-analyses will be of limited use to inform practice.  
Table 3.3 provides a summary of an excluded RCT on ketamine which may provide some insights into 
the effectiveness and safety of ketamine for induction of traumatic brain injury patients. Jabre et 
al.49 was the largest RCT found by the authors, with 655 critically ill patients who needed sedation 
for emergency intubation which were prospectively enrolled from 12 emergency medical services or 
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emergency departments and 65 intensive care units in France. Patients were randomly assigned by a 
computerised random-number generator list to receive 0.3 mg/kg of etomidate (n=328) or 2 mg/kg 
of ketamine (n=327) for intubation. 
Although the authors included a subgroup for trauma patients, they did not specify which patients 
within that subgroup were TBI patients. Thus, we cannot extract data regarding our population of 
interest. However, the authors found that the mean maximum Sequential Organ Failure Assessment 
(SOFA) score between the two groups did not differ significantly (10.3 [SD 3.7] for etomidate vs 9.6 
[SD 3.9] for ketamine; mean difference 0.7 [95% CI 0.0–1.4], p=0.056). Intubation conditions did not 
differ significantly between the two groups (median intubation difficulty score 1 [IQR 0–3] in both 
groups; p=0.70). The percentage of patients with adrenal insufficiency was significantly higher in the 
etomidate group than in the ketamine group (OR 6.7, 3.5–12.7, 95% Cl).  No serious adverse events 
with either study drug were recorded.  
The authors stated that ketamine is a safe and clinically valuable alternative to etomidate for 
endotracheal intubation in critically ill patients. Although TBI patients were included in their study, 
no adverse events or increases in mortality were observed in the ketamine group. This shows that 
ketamine likely has no negative effects for this specific subset of patients, or the rate of adverse 
events would have been higher in the ketamine group. Thus, ketamine is safe to use in critically ill 
patients, including patients who have suffered trauma. However, the question of whether ketamine 
may be harmful to TBI patients is still uncertain as it has not been specifically addressed in this RCT.  
Given that only one RCT found in the tier 3 searches was appreciably close to this review’s research 
question, the same trend found in tier 1 and 2 has continued through tier 3. Ongoing research, as in 
the case of Driver et al. 41 (if the authors include a subgroup for traumatic brain injury patients) have 
the potential to answer the research question in future. However, at this time there is a significant 
lack of empirical evidence and considerable knowledge gaps regarding the effectiveness and safety 
of ketamine in TBI patients in the prehospital and emergency department settings. Although cohort 
and other study designs can provide some evidence at less scientifically robust levels, RCTs remain 
the desired study design to provide an evidence base regarding the research question.  
The prehospital and emergency centre settings share many commonalities in the context of this 
review as adults with acute TBI emergencies would present to both settings in need of advanced 
airway management. However, the research bases for these two settings are significantly different. 
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Prehospital medicine is a ‘relatively new’ concept in terms of medicine as a whole, and as such does 
not have such an established evidence base when compared to the emergency centre. However, 
growing interest in improving prehospital care has significantly increased the research output in the 
prehospital field and it has become a fast-growing industry.  
Tiered approaches to searching and identification of studies for inclusion are a relatively novel 
review design. The tiered design offers significant benefits to both clinical policymakers and 
practitioners in healthcare as it is effective in answering research questions that require rapid 
responses for the healthcare industry. It is not limited to searching for primary evidence only, but 
includes study designs such as systematic reviews and clinical practice guidelines to inform the 
research question. It is possible, for the reviewer to then adopt, adapt or contextualise a clinically 
relevant clinical practice guideline’s recommendations to answer their research question, as 
opposed to searching for primary evidence, synthesizing that evidence and formulating their own 
recommendations to inform practice.  In terms of systematic searching, tiered approaches search for 
a wider variety of study designs, depending on the different study design/s searched for in each tier 
of inclusion. This adds to the thoroughness of a review, especially in cases where clinical questions 
require an answer within a limited timeframe and budget. Lower- and middle income countries can 
benefit from tiered approaches as recommendations made in CPGs and SRs from high-income 
countries can be adopted, adapted or contextualised to their unique circumstances.  
Limitations 
The study design was limited in search depth as articles published in languages other than English 
were excluded. Due to time and resource limitations, this was unfortunately not a feasible 
undertaking. Some articles published in other languages, where the abstract had been translated to 
English were found in the searches. However, these articles were not relevant to the research 
question. Also, grey literature was not included in this review.  
Although this review followed a tiered design which covered a wider variety of study designs sought 
for inclusion (CPGs, SRs and RCTs) as compared to a traditional systematic review where only RCTs 
are sought, searches were not continued for other study designs which may have been able to 
answer the research question, e.g. cohort studies. However, extending the searches past RCT level 
would significantly increase the resource and time requirements, and was not possible within the 
current scope.  
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Conclusions 
 
Implication for Practice 
We found no clinical practice guidelines, systematic reviews or randomised controlled trials which 
met our inclusion criteria in this review. The effectiveness and safety of ketamine for induction to 
facilitate intubation in adult TBI patients in the South African pre-hospital setting remains unclear. 
Due to a lack of empirical evidence, practitioners must be cautious and ensure that the benefit from 
its use outweighs the potential harm for a particular patient. 
Implication for Research 
Large, pragmatic randomised controlled trials are needed to provide an evidence base for 
ketamine’s safety and effectiveness. Ideally, these studies should be performed on TBI patients in 
the prehospital or emergency department settings, and should include both doctors and paramedics 
as the treating personnel.  
Ketamine as a bolus for induction to facilitate intubation in adult and/or paediatric patients should 
be compared to a reasonable induction agent available to the treating practitioners, such as 
etomidate, midazolam or propofol. As all-cause mortality would be a useful primary outcome; 
secondary outcomes such as intracranial pressure, cerebral perfusion pressure and mean arterial 
pressure could be helpful to improve our understanding of ketamine’s effectiveness and safety in TBI 
patients.  
Updates 
This review will be updated in two years and any new information regarding the research question 
will be provided in an update on this dissertation.  
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References to Included Studies 
No included studies found 
 
Tables 
Characteristics of Excluded Studies 
Table 1.1: Tier 1 table of excluded studies 
Study Reason for Exclusion 
Armstrong 2009 Literature review which reports on a checklist designed 
specifically for nurses (or an assistant) in the process of rapid 
sequence intubation.  
CADTH 2014  Literature review which reports on Ketamine being used as an 
analgesic agent and not an induction agent.  
Dash 2008 Literature review which details the different components of 
prehospital care in head injury patients.  
Green 2011 CPG regarding Ketamine dissociative sedation in the emergency 
department. Unclear methodology, reported in an end-user 
format. Unclear link between recommendations and evidence. 
Unable to identify clear CPG recommendations. Specifically deals 
with ketamine dissociative sedation in the ED, but does not 
report on the study population of interest (TBI patients).  
Harris 2015 Literature review of endotracheal intubation in general. No 
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recommendations were made regarding Ketamine which could 
be extracted. 
Hulme 2008 Literature Review regarding the resuscitation of patients after 
traumatic brain injury, pertaining to airway management, 
intracranial pressure, prognostic factors and prevention of 
secondary brain injury. No recommendations about Ketamine 
which pertains to the research question were made.  
Jensen 2010 CPG regarding general anaesthesia of emergency patients. 
Recommendations regarding pre-surgical management, 
induction of anaesthesia and airway management considerations 
are made.  
Lockey 2013 Literature review regarding controversies and challenges in the 
pre-hospital environment.  
Martin 2006 Descriptive study on patient-based outcomes of sedation and 
analgesia in German intensive care units. 
Mayglothling 2012 CPG regarding intubation of emergency trauma patients. 
However, there are no outcomes/ recommendations to extract 
regarding induction agents (including Ketamine) used in RSI.  
Paal 2009 Literature review on the use of anaesthetic agents in prehospital 
care. No recommendations were made regarding ketamine use 
in TBI patients. 
Pasternak 2007 Literature review regarding anaesthesiology practices and 
perioperative care of neurosurgery patients. 
RDFS 2008 CPG on the recommendations of emergency care from the Royal 
Doctor Flying Service. Not relevant to our research question.   
Scarponcini 2011 Literature Review regarding the incorporation of an emergency 
pharmacist in trauma resuscitation.  
Seder 2012 Resembles an end-user document, which outlines the process of 
deciding to intubate, sedation and intubation. Does mention 
Ketamine, but makes no recommendations regarding its use.  
Tobin 2013 Literature review regarding Ketamine use in head-injured 
patients. No recommendations were made. 
Wenzel 2009 Commentary on an RCT published by Jabre et al 2009, which in 
turn compared mean Sequential Organ Failure Assessment 
(SOFA) score after Ketamine/Etomidate Administration 
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Table 1.2: Tier 2 table of excluded studies 
Study  Reason for Exclusion 
Aroni et al. 2009 Literature review of the pharmacological aspects of Ketamine 
with regards to its effects on the central nervous system, 
haemodynamic effects and use as pain management agent.  
Bedell 2002 Literatures review which reports on the interventions which may 
be likely to improve survival after a significant TBI, such as 
prevention of hypotension, hypoxia and hypoglycaemia.  
Chang et al. 2013 Literature review regarding neuroprotective effects of ketamine 
in traumatic brain injured patients. Not applicable to study 
research question. 
Cohen et al. 2015 Systematic review of Ketamine use in ICU and operating room 
(OR) patients, and although it reports data which is relevant to 
our research question, it only reports these outcomes for ICU 
and OR patients and not the population of interest for our 
review.  
Cormio 1997 Literature review regarding the pathological processes involved 
in traumatic brain injuries, specifically regarding secondary brain 
injury. 
Craven 2007 End-user document for clinicians to familiarise themselves with 
Ketamine, its use and its effects. It includes practical examples 
and scenarios to stimulate critical thinking regarding the use of 
Ketamine 
Dash 2008 Literature review reporting on the challenges faced to achieve 
prehospital emergency medical care in India. Although Ketamine 
is mentioned, it is not done so in the context which would make 
it relevant to our review.  
Filanovsky et al. 2010 Literature review regarding ICP levels after ketamine was 
administered in ICU patients. A search strategy was reported, 
however it followed a non-systematic method. 
Himmelseher 2005 Systematic review of ketamine use and cerebral effects in 
neurosurgical patients. 
Hughes 2011 Not a systematic review, but what was referred to by the study 
author as a “short-cut review”, regarding the use of ketamine as 
an induction agent for intubation in adults with traumatic brain 
injury. Although the review matches our research question 
closely, they did not perform a review of RCTs, but based their 
results on a case report and a study which does not apply to our 
research question. Unclear methods.  
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McIntosh 1996 Literature review regarding pharmacological manipulation of key 
neurotransmitters in the brain that can attenuate neuronal 
damage. Not relevant to our research question.  
McIntosh 1998 This article is related to the one above, which was previously 
published by the same author. Not Relevant to our research 
question. 
Morris et al. 2009 Literature review regarding induction with ketamine in 
hemodynamically unstable patients and the effect it has on the 
patient’s hemodynamics. Not the population of interest.  
Roberts 2011 Systematic review of critically ill ICU patients with severe head 
injury who were sedated using ketamine, propofol, etomidate 
and other sedatives. Not the review’s population of interest. 
Sehdev 2006 Literature Review of Ketamine use in head injured patients in 
the ED to facilitate intubation. This study did not report on any 
RCT, which meant its exclusion.  
Sih 2011 Systematic review where the outcomes were narratively 
reported. Although it assesses Ketamine use in the ED to 
facilitate endotracheal intubation, none of the included studies 
reported on head injury patients.  
Urwin 2004 Literature review with methods not clearly stated. Describes the 
effects of multiple induction agents in head injury patients. Does 
not report a search strategy, appraisal method/s or 
inclusion/exclusion criteria.  
Vutskits 2014 Not relevant to our research question. Primarily deals with 
medications used for neuroprotection in in head-injured 
patients.  
Wang et al. 2014 Systematic review, which much like Cohen et al 2015, reports on 
outcomes which are relevant to our research question. 
However, as above, it only reports these outcomes for ICU, 
paediatric and patients which do not fall within the populations 
of interest for the review.  
Zeiler 2014 Systematic review. However, it only reports on patients in the 
ICU and not the population of interest for the Review 
 
Table 1.3: Tier 3 table of excluded studies 
Abdennour 2008 Article Published in French 
Abdusoglu 2012 Does include ketamine as intervention, however ketamine as 
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given as an analgesic locally to prevent pain from propofol or 
rocuronium injections. Thus, does not apply to our PICO. 
Albanese 2004 Article Published in French 
Bourgoin 2003 Ketamine not given as an induction agent or as a bolus. Article 
does not deal with intubation, but rather with Ketamine given as 
a bolus in ICU to determine its effects on ICP.   
Freund 2014 Does include Ketamine in the study, but only reports on 
outcomes related to Etomidate and relative adrenal 
insufficiency.  
Gunning 2007 Case Report of a patient involved in a trench entrapment - not an 
RCT. 
Jabre 2009 Study very close to our review’s inclusion criteria. Acutely ill 
patients as population, which includes trauma patients. 
However, does not include head injured patients as a subgroup 
in the trauma category, i.e. cannot extract data relevant to our 
PICO.  
Matthes 2012 Article is published in German 
McDermott 2013 Literature review regarding ketamine use as an induction agent 
in head-injured patients. Methods unclear. No delineation given 
of outcomes, setting, comparators or how the intervention was 
applied (doses, time over which dose was given and clinical 
setting) 
 
Table 2.1: Table of Clinical Practice Guidelines (Tier 1) on Ketamine 
 
Reference     Green, et al 52 
Purpose/Scope To describe the best available evidence and perspectives about optimal dissociative 
sedation practice in the Emergency Department 
Guideline Questions None specified 
Methods Assembled a committee of 4 senior ketamine researchers. 
 
Searched  
● MEDLINE: 
● January 2003 to November 2010, using the single search term “Ketamine”. 
● Tables of contents of the leading emergency medicine and anaesthesiology journals 
during the same period.  
● Reference lists of all identified articles for additional relevant articles.  
 
Study Inclusion and Grading 
Study inclusion/exclusion was debated by e-mail and during a group meeting on September 
12, 2010. They graded the availability and strength of scientific evidence from the medical 
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literature, using descriptive terms adapted from the American Society of Anaesthesiologists 
 
Summary 
Recommendations 
As per table 1.1, Tier 1 table of excluded studies, there is an unclear link between 
recommendations and the evidence. The authors are unable to identify clear 
recommendations from the CPG. 
 
Comments This CPG resembles and end-user document, where the focus is not specific 
recommendations based on the literature and evidence, but rather to produce a guideline 
for the procedure in which to identify the need for ketamine dissociative sedation, 
indications, contraindications, administration and techniques/ manners in which to reduce 
the incidence of adverse effects. Therefore, it is reasonable to consider this a clinical 
protocol and not a true CPG, as recommendations are not clearly stated.  
It is, however, a very informative document and covers the topic in sufficient depth to be 
useful as a protocol for healthcare practitioners who are not well versed in Ketamine use 
and its effects, or unsure of its application and role in their clinical setting. 
 
Reference     Mayglothling, et al 53 
Purpose/Scope The goals of the work group were to develop evidence-based guidelines to (1) characterize 
patients in need of ETI and (2) delineate the most appropriate procedure for patients 
undergoing ETI.  
Guideline Questions 1. Are the 2002 guidelines still valid, and is there any new evidence to change the level of 
the previous recommendations? 
2. Is direct laryngoscopy (DL) still the preferred method for ETI in trauma?  
3. What is the role of newly introduced airway adjuncts, such as blind insertion 
supraglottic devices and video laryngoscopy? 
4. Are there pharmacologic agents used for intubation that should be recommended for 
or against in the setting of acute injury? 
5. What is the role of prehospital ETI? 
Methods Searches 
● MEDLINE - Citations published between January 2001 and December 2011. This 
included a combination of MESH headings and title words. 
● In addition to the MEDLINE search, bibliography of reviews, letters to the editor, and 
meta-analyses were used to identify other relevant patient investigation articles. If an 
article investigated trauma and medical patients, the article was included if the trauma 
patient cohort was at least 50% or if the study included a subgroup analysis on the 
specific trauma population. 
● Articles and recommendations were classified as described in the EAST primer on using 
evidence-based outcome measures to develop practice management guidelines. 
 
Summary 
Recommendations 
● In terms of airway management, it is recommended that a careful airway assessment 
be conducted before efforts to secure the airway are initiated. (Level 2) Proper 
preparation in terms of airway devices, techniques, medications and bail-out options 
should be made for a suspected difficult airway. (Level 2) 
● In terms of indications of endotracheal intubation (ETI), it is indicated for trauma 
patients with airway obstruction, hypoventilation, persistent hypoxaemia, GCS ≤ 8, 
severe haemorrhagic shock and cardiac arrest. ETI is also indicated for patients with 
smoke inhalation and airway obstruction, GCS ≤ 8, >40% burns, prolonged time to 
definitive care and impending airway obstruction (Level 1) 
● ETI is also indicated for trauma patients with facial or neck injury with potential airway 
obstruction, GCS ≤ 9, persistent combativeness despite pharmacological agent use, 
respiratory distress, preoperative management, and cervical spine injuries with 
respiratory compromise. (Level 3) 
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● In terms of procedural options, ETI by direct laryngoscopy is the preferred method for 
trauma patients. Rapid sequence intubation (RSI) should be used unless there are 
specific contraindications to its use. There are no recommendations regarding the use 
of specific induction agents used for RSI in trauma. Succinylcholine is the 
recommended agent of choice for neuromuscular blockade, in the absence of any 
contraindications to its use. 
● For safe and effective ETI, experienced personnel should be available, pulse-oximetry 
be monitored, cervical neutrality maintained, confirmation of tube placement be done 
by both auscultation and end-tidal CO2 monitoring and continuous end-tidal CO2 
monitoring be maintained continuously. 
● Cricothyroidostomy is indicated if direct laryngoscopy and alternative methods fail. 
Airway rescue devices such as blind insertion devices and intubation adjuncts should be 
used when direct laryngoscopy fails. (Level 2) 
● Video laryngoscopy may offer significant advantages over Direct laryngoscopy.  
● Superior views of the glottis, higher intubation success rates for patient with confirmed 
difficult airway, and higher intubation success rates by inexperienced airway providers. 
 
Comments This particular CPG made no recommendations regarding the agents used for induction in 
intubation or rapid sequence intubation. Thus, it was excluded from the study. 
However, it does make recommendations regarding intubation in head injured patients, and 
specifically regarding how to prevent adverse events before, during and after intubation of 
these patients.  
It would be helpful to both inexperienced and experienced provides to improve their 
management of the airway in traumatic brain injury patients. 
 
Reference     Jensen, et al 50 
Purpose/Scope The aim of this CPG was to find the evidence and latest scientific information for their 
current anaesthetic management of emergency patients, and thereby to provide 
anaesthesiologists in the Nordic countries with a mutual understanding and a standardised 
protocol to anaesthetize these patients 
Guideline Questions None specified 
Methods Searches 
● PubMed, inclusive of Mesh, and the Cochrane Library from August 1961 to May 2009 
● Cross references from relevant studies has been used.  
● Grading of evidence and grading of recommendations were performed according to a 
system first used by Bell et al.
54
 According to this system, evidence is graded from A to 
E, where recommendation grade A indicates a recommendation based on the best 
evidence.  
● The individual chapters were written in drafts, and after initial discussions via mail, a 
consensus meeting was held. Evidence was assessed and grading of recommendations 
was decided. Consensus opinion was used in the many topics where high-grade 
evidence was unavailable.  
● The specific grading of evidence and grading of recommendation can be found in the 
individual chapters, where a draft with recommendations was presented at the 30th 
Congress of SSAI, June 2009.  
● Comments from this presentation were incorporated into the next draft, and this draft 
was presented for comments and critique on the SSAI website from August until 
November 2009. 
Summary 
Recommendations 
Pre-operatively 
● Anaesthesia for emergency patients should be given by, or under very close supervision 
by, an experienced anaesthesiologist. Haemodynamic and airway-related 
complications should be anticipated. Alternative plans and adequate equipment for 
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dealing with complications must be ready.  
● In patients with an increased risk of aspiration, precautions to avoid regurgitation must 
be taken.  
● Unless the patient has an increased risk of aspiration, patients scheduled for 
emergency surgery can be considered fasting.  
● Pre-operative gastric emptying with an orogastric or a nasogastric tube is rarely 
indicated. 
  
Pre-oxygenation and cricoid pressure 
● Pre-oxygenation is initiated by explaining the procedure to the patient.  
● Avoid a leak between the patient’s face and the oxygen mask.  
● Either tidal volume breathing for 3 min or eight deep breaths over 60 s with an oxygen 
flow of at least 10 l/min should be used.  
● Non-invasive positive pressure ventilation or the application of positive end-expiratory 
pressure can be considered in morbidly obese or critically ill hypoxic patients. 
● Pre-oxygenation in obese patients should be performed in the head-up position; 
otherwise, there is no advantage of one placement over the other.  
● The use of cricoid pressure is not considered mandatory, but can be used on individual 
judgement.  
● If used, the cricoid pressure must be used correctly, and the pressure should be 
released if ventilation or laryngoscopy and intubation are difficult.  
● Cricoid pressure should also be released before inserting the Laryngeal Mask Airway 
should initial attempts at tracheal intubation prove Unsuccessful. 
 
Drugs 
● The hypnotic drug has a minor influence on intubation conditions, and should be 
chosen on other grounds. 
● Thiopentone seems to be a better choice than propofol to avoid hypotension following 
induction.  
● On the other hand, propofol is a better choice than thiopentone to avoid a 
cardiovascular stress response in patients with ischaemic cardiac disease.  
● Ketamine should be considered for hypovolaemic patients (hypovolaemic shock or pre-
shock) or for cardiovascular unstable patients when there is no time or possibility of 
pre-operative optimization. 
● An opioid can be used to reduce the stress response following intubation.  
● A neuromuscular blocking agent is used to optimize intubation conditions.  
● For optimal intubation conditions, succinylcholine 1–1.5 mg/kg is preferred over other 
neuromuscular blocking drugs.  
● Where contraindications to succinylcholine exist, rocuronium 0.9–1.2 mg/kg is an 
adequate alternative.  
 
Anaesthesia outside the operation room 
● Rapid sequence intubation is considered the safest method. 
● Awake intubation can be performed in selected cases.  
● For induction of anaesthesia, all available induction agents can be used. 
 
End of anaesthesia 
Take precautions also at the end of anaesthesia to avoid haemodynamic and airway-related 
complications as well as regurgitation. 
 
Comments Of the three CPGs which were discussed here, this CPG reports their methods and results 
significantly better than the above two. However, these recommendations are made 
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without a clear clinical setting identified.  
It is a very informative document regarding the current practices in the Scandinavian 
anaesthesia setting. However, as the ‘current Scandinavian anaesthetic management of 
emergency patients’  is not specified in the document, nor the evidence and literature as to 
why that is the norm, it is impossible to apply the recommendations to any other clinical 
setting than Scandinavia.  
However, it does provide some insights into anaesthesia of emergency patients, and 
emphasises the importance of having standardised practice regimes within a healthcare 
system/speciality.   
Table 2.2: Table of Systematic Reviews (Tier 2) on Ketamine 
Reference Cohen, et al. 2015 51 
Research Question Does ketamine raise intracranial pressure or worsen neurologic outcomes? 
Intervention/Comparison 
description 
Ketamine used as an infusion or bolus dose compared to other sedative agents in patients 
who had previously been intubated or who were being intubated at data collection. 
Results Intracranial pressure and cerebral perfusion pressure  
Three randomized trials and 5 prospective controlled trials. 
Studies examined the relationship between ketamine and comparator induction agents with 
respect to intracranial and cerebral perfusion pressures, and reported data on 168 patients.  
These studies found no differences in mean daily intracranial or cerebral perfusion 
pressures. 
 
Neurologic outcomes 
Four of the 5 included randomized trials reported data on neurologic outcomes reporting 
data on 824 patients.  
Studies used different neurologic outcome scales and collected data at different points, 
precluding any pooling of data.  
However, within each individual included study, none of them reported statistically 
significant difference between the intervention and control groups (based on the 
neurological outcome scale they used). 
 
ICU length of stay  
Two randomized studies reported ICU length of stay as a study outcome (n¼145). Neither 
study found a difference in length of stay. 
 
Mortality 
Two randomised trials reported mortality data on 680 patients. Neither study found a 
difference in Mortality.  
 
Comments This study had very similar outcome measures to this review. However, all the studies they 
included in their systematic review were not the population of interest for this review. Thus, 
it could not be included.  
However, this study provides a great deal of insight into the safety and effectiveness of 
Ketamine used to facilitate intubation in other patient populations, such as surgical or ICU 
patients.  
In none of the outcome measures, intracranial pressure and cerebral perfusion pressure, 
neurologic outcomes, ICU length of stay and mortality, did they report in difference in the 
outcomes between ketamine and comparison agents.  
Without empirical evidence for the pre-hospital or emergency department settings, 
ketamine effectiveness and safety in these settings cannot be clearly stated.  
However, it is promising to note that, at least in surgical and ICU patients, these outcomes 
have shown no difference. This article helps to highlight one of the current gaps in 
knowledge regarding Ketamine, as it not yet clear what its effectiveness and safety  in the 
population of interest is. 
 
Reference Wang et al. 2014 55 
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Research Question What are the effects of ketamine on cerebral hemodynamics in comparison with opioids in 
patients with or without neurological injury? 
Intervention/Comparison 
description 
RCTs conducted in humans of cerebral hemodynamics comparing ketamine with opioids, 
regardless of whether the subjects were head injured, ventilated, underwent surgery, or 
received additional medications. The study analysed the ICP levels after administration of 
ketamine or opioids. The dose, timing, and other details of anaesthesia drugs were not 
limitations. 
Results ICP 
Meta-analysis showed that ketamine led to the same ICP levels as did opioids, which was 
one of the common agents for sedation (mainly sufentanil and fentanyl) (MD = 1.94; 95 % 
CI, -2.35, 6.23; I2 = 85 %; P = 0.38)  
 
MAP 
Data were derived from three articles for the analysis of MAP. No statistical significance was 
found in MAP values between the groups (MD = 0.99; 95 % CI, -2.24, 4.22; I2 = 0 %; P = 
0.55). 
 
CPP 
Data from four articles were used for the analysis of CPP. Ketamine administration was 
comparable with opioids in the maintenance of CPP (MD = -1.07; 95 % CI, -7.95, 5.8; I2 = 83 
%; P = 0.76) 
Comments A random effects meta-analysis was conducted on intensive care patients comparing 
ketamine to opioids for ICP for MAP and CCP, a fixed effects meta-analysis was conducted 
on intensive care patients comparing ketamine to opioids.  
Although our review did not use cerebral heamodynamics following ketamine 
administration as an outcome,  knowing the effects of Ketamine on ICP, MAP and CPP could 
assist greatly with describing Ketamine’s effects on the body and brain.  
 
 
Table 2.3: Table of Randomised Controlled Trials (Tier 3) on Ketamine 
Reference Jabre et al. 2009 56 
Research Question What is the early and 28-day mortality of a single dose ketamine compared to etomidate, 
for emergency endotracheal intubation of critically ill patients? 
 
Intervention/Comparison 
description 
Patients were randomly assigned in a 1:1 ratio to either etomidate (Lipuro, B Braun Medical, 
Boulogne, France) administered as a 0·3 mg/kg intravenous bolus, or to ketamine (Ketalar, 
Panpharma, Fougères, France) administered as a 2 mg/kg intravenous bolus. 
 
Results See Reference 
 
Comments To date, this is the largest RCT the authors have found which compares ketamine to another 
induction agent (etomidate) currently being used in the South African pre-hospital setting.  
Although this study included a subgroup of trauma patients, the authors did not specify 
which subset of the trauma patients had with traumatic brain injuries. This meant the 
exclusion of the article from the review.  
However, this RCT is very informative as it compares ketamine and etomidate in a 
generalised population group (critically ill patients), improving its external validity to more 
patient populations than a study with a very specific study population. 
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Appendices 
 
Appendix 1: Search Strategies 
Appendix 1.1: Clinical Practice Guidelines (Tier 1) 
1.   Ketamine OR Ketalar OR Brevinase AND Head Injur* OR Brain Injur* OR 
traumatic brain injur* OR Head trauma 
  
Adapted according to search results as CPG databases are less refined 
Appendix 1.2: Systematic Reviews (Tier 2) 
1.    Cochrane Library 
(((((("Ketamine"[Mesh]) OR ketamine[Title/Abstract])) OR Brevinase[Title/Abstract]) 
OR Ketalar[Title/Abstract])) AND 
(((((("Craniocerebral Trauma"[Mesh] OR "Head Injuries, Penetrating"[Mesh] OR 
"Head Injuries, Closed"[Mesh])) OR head injur*[Title/Abstract]) OR head 
trauma[Title/Abstract]) OR traumatic brain injur*[Title/Abstract]) OR "Brain 
Injuries"[Mesh]) 
Appendix 1.3:Randomised Controlled Trials (Tier 3) 
1.    Pubmed 
(((((("Ketamine"[Mesh]) OR ketamine[Title/Abstract])) OR Brevinase[Title/Abstract]) 
OR Ketalar[Title/Abstract])) AND (((((("Craniocerebral Trauma"[Mesh] OR "Head 
Injuries, Penetrating"[Mesh] OR "Head Injuries, Closed"[Mesh])) OR head 
injur*[Title/Abstract]) OR head trauma[Title/Abstract]) OR traumatic brain 
injur*[Title/Abstract]) OR "Brain Injuries"[Mesh]) 
 
2.    Scopus and Cochrane CENTRAL Library 
ketamine  OR  brevinase  OR  ketalar  AND  craniocerebral  trauma  OR  head  injur*  
OR  head  trauma  OR  traumatic  brain  injur*  OR  brain  injur* 
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Appendix 2: Aggregate Scores and Graphical Representation of Quality of 
Reporting of Clinical Practice Guidelines (AGREE II) 
 
Study Name Domain 1 Domain 2 Domain 3 Domain 4 Domain 5 Domain 6  Overall CPG 
Assessment 
Score 
Green, et al. 
2011 
25% 11.1% 18.8% 19.4% 10.4% 20.8% 2 out of 7 
Mayglothling, 
et al. 2012 
33.3% 5.5% 36.5% 34.8% 0% 50% 2 out of 7 
Jensen, et al. 
2010 
30.6% 25% 47.9% 63.9% 13% 0% 3 out of 7 
 
 
Figure 4: Graph of Aggregate Scores Obtained by 3 CPGs for AGREE II 
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